![Scott Daniel Cormack](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Scott Daniel Cormack
Direttore/Membro del Consiglio presso
PC-TRiADD
Profilo
Scott Daniel Cormack is the founder of three companies.
OncoGenex Technologies, Inc. was founded in 2000, For Tomorrow was founded in 1999, and OncoGenex Pharmaceuticals, Inc. was founded in 1991.
At OncoGenex Technologies, Inc., he held the title of President & Chief Executive Officer from 2000 to 2008.
At OncoGenex Pharmaceuticals, Inc., he held the title of President, CEO, Secretary, Treasurer & Director from 2014 to 2017.
At For Tomorrow, he held the title of President in 1999.
Currently, he holds positions as Director-Prostate Centre at Vancouver General Hospital, Director at PC-TRiADD, and Director at Novelogics Biotechnology, Inc. He previously held positions as Chairman, President & Chief Executive Officer at Salpep Biotechnology, Inc. from 2000 to 2001, Director at LifeSciences British Columbia in 2008, Director at Fe Pharmaceuticals (Canada), Inc., Director at Aurinia Pharmaceuticals, Inc. from 2012 to 2014, Director at Achieve Life Sciences, Inc. from 2008 to 2021, Chief Operating Officer at NeuroSpheres Ltd. from 1995 to 1998, Vice President at Milestone Medica Corp.
from 1998 to 2001, and Manager-Technology Immunomodulators at Vetrepharm, Inc. from 1986 to 1991.
He received his undergraduate degree from the University of Alberta in 1986.
Posizioni attive di Scott Daniel Cormack
| Società | Posizione | Inizio |
|---|---|---|
PC-TRiADD
 PC-TRiADD Miscellaneous Commercial ServicesCommercial Services Operates as a cancer treatment research center | Direttore/Membro del Consiglio | - |
Vancouver General Hospital | Corporate Officer/Principal | - |
Novelogics Biotechnology, Inc.
 Novelogics Biotechnology, Inc. BiotechnologyHealth Technology Develops antibody immunotherapies for cancer | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Scott Daniel Cormack
| Società | Posizione | Fine |
|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. | Direttore/Membro del Consiglio | 11/05/2021 |
OncoGenex Pharmaceuticals, Inc.
 OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapies that address treatment resistance in cancer patients | Amministratore Delegato | 01/08/2017 |
| AURINIA PHARMACEUTICALS INC. | Direttore/Membro del Consiglio | 01/01/2014 |
LifeSciences British Columbia
 LifeSciences British Columbia BiotechnologyHealth Technology Supports and represents the biotechnology and greater life sciences community of Britsh Columbia | Direttore/Membro del Consiglio | 02/10/2008 |
OncoGenex Technologies, Inc.
 OncoGenex Technologies, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Amministratore Delegato | 22/08/2008 |
Formazione di Scott Daniel Cormack
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
78
Relazioni di 1° grado
15
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 15 |
|---|---|
NeuroSpheres Ltd. | |
University of Alberta
 University of Alberta Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OncoGenex Technologies, Inc.
OncoGenex Technologies, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Milestone Medica Corp.
 Milestone Medica Corp. Investment ManagersFinance Acts as an alternative investment manager | Finance |
LifeSciences British Columbia
LifeSciences British Columbia BiotechnologyHealth Technology Supports and represents the biotechnology and greater life sciences community of Britsh Columbia | Health Technology |
Vancouver General Hospital | |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapies that address treatment resistance in cancer patients | Health Technology |
Salpep Biotechnology, Inc. | |
Vetrepharm, Inc. | |
For Tomorrow | |
Fe Pharmaceuticals (Canada), Inc.
 Fe Pharmaceuticals (Canada), Inc. Pharmaceuticals: MajorHealth Technology Develops patented iron-binding molecules that remove biologically available iron, making pathogens susceptible to existing antibiotics | Health Technology |
Aurinia Pharmaceuticals, Inc.
 Aurinia Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company, which focuses on discovery and development of immunomodulating therapeutics | Health Technology |
PC-TRiADD
PC-TRiADD Miscellaneous Commercial ServicesCommercial Services Operates as a cancer treatment research center | Commercial Services |
Achieve Life Sciences, Inc.
 Achieve Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes cytisinicline for smoking cessation and nicotine addiction | Health Technology |
Novelogics Biotechnology, Inc.
Novelogics Biotechnology, Inc. BiotechnologyHealth Technology Develops antibody immunotherapies for cancer | Health Technology |
